Last updated on May 2018

Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT Therapy With Acarovac Hausstaubmilbe


Brief description of study

Non-interventional Study to Assess the Tolerability and the Safety Profile of SCIT therapy With Acarovac Hausstaubmilbe

Detailed Study Description

This prospective open multi-centre non-interventional study was initiated to document the tolerability and the safety profile of the subcutaneous allergen-specific immunotherapy with Acarovac in house dust mite allergic patients in routine medical care.

During the up-dosing phase with Acarovac, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.

Data on tolerability are documented by the physicians.

Clinical Study Identifier: NCT03127436

Contact Investigators or Research Sites near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.